Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Pentadeca arginate (PDA) cycle length: what human studies ran

Not approved — research use only
Short answer: there is no established Pentadeca arginate (PDA) cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Pentadeca arginate (PDA) combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Pentadeca arginate (PDA) cycle length?
No. We found no human studies that report a treatment duration for Pentadeca arginate (PDA).
What is the longest human study of Pentadeca arginate (PDA)?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Pentadeca arginate (PDA) dosing reference Full research page

References

  1. PubMed search for 'pentadeca arginate', 'pentadecapeptide arginate', 'pentadeca-arginate', 'BPC-157 arginate' and 'BPC 157 arginine salt' (0 records, searched 2026-10-24) PubMed (NCBI E-utilities). 2026
  2. PubChem name lookup for 'pentadeca arginate' and 'pentadecapeptide arginate' (no CID found, 2026-10-24) PubChem. 2026
  3. ClinicalTrials.gov search for 'pentadeca arginate' (no studies returned, 2026-10-24) ClinicalTrials.gov. 2026
  4. PubChem compound record for BPC-157 (CID 9941957) PubChem. 2026
  5. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety Acta Orthop Belg. 2026
  6. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Pharmaceutics. 2026
  7. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) FDA. 2026
  8. Tractatenblad 2026 Nr. 25: Anti-doping convention (ETS No. 135), amendment to the appendix - The 2026 Prohibited List, World Anti-Doping Code (English text; entry into force 1 January 2026) Tractatenblad van het Koninkrijk der Nederlanden (official government publication). 2026